Author(s): Punit Jaiswal, Achal Mishra, Disha Kesharwani, Swarnali Das Paul


DOI: 10.52711/0974-360X.2023.00251   

Address: Punit Jaiswal1, Achal Mishra1, Disha Kesharwani2, Swarnali Das Paul3
1SSTC-Faculty of Pharmaceutical Sciences, Bhilai (C.G.) India.
2Columbia Institute of Pharmacy, Raipur (C.G.) India.
3Shri Shankaracharya College of Pharmaceutical Sciences, Bhilai (C.G.) India.
*Corresponding Author

Published In:   Volume - 16,      Issue - 3,     Year - 2023

Over the last few years, the focus over the ocular delivery system has been increased exponentially. The reason behind this interest may be due to noninvasive nature of this administration route along with its patient compatibility. The side effects associated are also fewer. However maintenance of its efficiency still remains a challenging task for the formulation scientists as there are number of external barriers like tear, blood flow in conjunctiva, blood retinal barrier, film clearance etc. Along with these problems, since the solubility of the drug also affects the efficiency of the formulation, nanosuspension is an attractive approach to resolve these problems. Nanosuspension contains a poorly soluble drug suspended in dispersion medium. This colloidal system improves the poor solubility of the drug to a great extent with alteration of its pharmacokinetic profile, its safety and efficacy.

Cite this article:
Punit Jaiswal, Achal Mishra, Disha Kesharwani, Swarnali Das Paul. Overview on Ocular Drug Delivery through Colloidal Nano-Suspension. Research Journal of Pharmacy and Technology 2023; 16(3):1533-9. doi: 10.52711/0974-360X.2023.00251

Punit Jaiswal, Achal Mishra, Disha Kesharwani, Swarnali Das Paul. Overview on Ocular Drug Delivery through Colloidal Nano-Suspension. Research Journal of Pharmacy and Technology 2023; 16(3):1533-9. doi: 10.52711/0974-360X.2023.00251   Available on:

1.    Hughes PM, and Mitra AK. Overview of ocular drug delivery and iatrogenic ocular cytopathologies. In: Mitra AK (2nd edition) Ophthalmic Drug Delivery Systems. New York: M. Dekker, Inc.1993;1-27.
2.    Rajashri R. Kulkarni, Dipti G. Phadtare, Ravindra B. Saudagar. A Novel Approach Towards Nanosuspension. Asian J. Pharm. Res. 5(4): 2015;186-194.
3.    Sarika V. Khandbahale. A Review- Nanosuspension Technology in Drug Delivery System. Asian J. Pharm. Res. 2019; 9(2): 130-138.
4.    Lang JC. Ocular drug delivery: conventional ocular formulations.Adv. Drug Delivery Rev. 1995;16(1):39–43.
5.    Anand BS, Mitra AK,Dias CSet al. Effect of mono- and diacylation on the ocular disposition of ganciclovir: physicochemical properties, ocular bioreversion, and antiviral activity of short chain ester prodrugs. J. Pharm. Sci. 2002; 91(3): 660–668.doi: 10.1002/jps.10072.
6.    Maurice DM, Mishima S. Ocular pharmacokinetics, in: M.L. Sears (Ed.), Handbook of experimental pharmacology, Springer Verlag, Berlin-Heidelberg. 1984; 69: 116–119.
7.    Smita S. Aher, Sagar T. Malsane, R. B. Saudagar. Nanosuspension: An Overview. Asian J. Res. Pharm. Sci. 2017; 7(2):81-86.
8.    Vijay Shinde, P Amsa, S Tamizharasi, D Karthikeyan, T Sivakumar, Abhijit Kosalge. Nanosuspensions: A Promising Drug Delivery Strategy. Research J. Pharm. and Tech. 3(1): Jan. - Mar. 2010; Page 39-44.
9.    V. Rajesh Babu, Aleem M.A, Syeda Rana Nikhat, Sana Aslam, Mohib Khan. Nanosuspension Technology for Poorly Water Soluble Drugs: An Overview. Research J. Pharm. and Tech. 4(4): April 2011; Page 515-520.
10.    Patel A, Cholkar K, Agrahari V, and Mitra A.K. et al. An overview Ocular drug delivery systems. World J Pharmacol. 2013; 2(2): 47–64. doi: 10.5497/wjp.v2.i2.47
11.    Katteboinaa S. Drug nanocrystals: A novel formulation approach for poorly soluble drugs, International journal of pharmtech research. 2009; 1(3): 682-694.
12.    Dinesh kB. Nanosuspension Technology in Drug Delivery System, Nano-science and Nanotechnology: An International Journal. 2013; 3(1): 1-3.
13.    Patel AP. A review on drug nanocrystal a carrier free drug delivery, IJRAP. 2011; 2(2): 448-458.
14.    Dhiman S. Nanosuspension: a recent approach for nano drug delivery system, International journal of current pharmaceutical research. 2011; 3: 96-101.
15.    Maravajhala V, Papishetty S, Bandlapalli S et al.  Nanotechnology in development of drug delivery system.International Journal of Pharmaceutical Science and Research. 2012; 3(1): 84-96.
16.    Dubey R. Impact of Nanosuspension technology on drug discovery and development. Drug Delivery Technol. 2006; 6: 65–71.
17.    Kipp J, Wong JCT, Dotty MJ, Rebbech Cl et al. Micro-precipitation Method of Preparing Submicron Suspension, U.S. PATENT; 2003.
18.    KesisoglouF, Panmai S, Wu Y et al. Nanosizing—oral formulation development andbiopharmaceutical evaluation, Adv. Drug Deliv. Rev. 2007; 59(7): 631–644.doi: 10.1016/j.addr.2007.05.003.
19.    Ganta S, Paxton JW,Baguley BC, Garg S et al. Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery, Int. J. Pharm. 2009; 367 (1–2): 179–186.
20.    Hecq J, Deleers M, Fanara D, Vranckx H, Boulanger P, Lamer SL, Amighi K et al. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base, Eur. J. Pharm. Biopharm. 2006; 64(3): 360–368.
21.    Yang W, Tam J, Miller DA, Zhou J, MC Conville JT, Johnston KP, Williams Iii RO et al. High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers, Int. J. Pharm. 2008; 361(1–2): 177–188.
22.    Rabinow BE. Nanosuspensions in drug delivery, Nat. Rev. Drug Discov. 2004; 3(9): 785–796.
23.    Li XS, Wang JW, Shen ZG, Zhang PY,Chen JF, Yun J et al. Preparation of uniform prednisolone microcrystals by a controlled micro precipitation method, Int. J. Pharm. 2007; 342(1–2): 26–32.doi: 10.1016/j.ijpharm.2007.04.025.
24.    Banavath H, Sivarama RK, Tahir A, Sajid A, Pattnaik G et al. Nanosuspension: an attempt to enhance bioavailability of poorly soluble drugs, International Journal of Pharmaceutical Science and Research.2010;1(9):1-11.
25.    Shegokar R, Müller RH. Nanocrystals: Industrially feasible multifunctional formulation technology for poorly soluble actives, International Journal of Pharmaceutics, 399, 2010, 129–139.doi: 10.1016/j.ijpharm.2010.07.044.
26.    Chingunpituk J. Nanosuspension Technology for Drug Delivery, Walailak J Sci & Tech. 2007; 4(2): 139-153.DOI:10.2004/wjst.v4i2.94.
27.    Abhijit AD, Kulkarni RM, Patravale B et al. Nanosuspensions: a promising drug delivery strategy, Journal of Pharmacy and Pharmacoloy. 2004; 56(7): 827–840.doi: 10.1211/0022357023691.
28.    Paun J.S., Tank H.M. Nanosuspension: An Emerging Trend for Bioavailability Enhancement of Poorly Soluble Drugs. Asian J. Pharm. Tech. 2(4): Oct. - Dec. 2012; Page 157-168.
29.    Suryakanta Nayak, Dibyasundar Panda, Ajaya Kumar Patnaik. Nanosuspension – Preparation, In Vitro and Ex Vivo Evaluations of Felodipine Hydrochloride. Research J. Pharm. and Tech. 8(1): Jan. 2015; Page 38-43.
30.    Harshil M. Patel, Bhumi B. Patel, Chainesh N. Shah, Dhiren P. Shah. Nanosuspension Technologies for Delivery of Poorly Soluble Drugs- A Review. Research J. Pharm. and Tech. 2016; 9(5): 625-632.
31.    Pawar Pravin, Yadav Adhikrao, Gharge Varsha. Different Techniques for Preparation of Nanosuspension with Reference to its Characterisation and various Applications - A Review. Asian J. Res. Pharm. Sci. 2018; 8(4): 210-216.
32.    Vijay Shinde, P Amsa, S Tamizharasi, D Karthikeyan, T Sivakumar, Aniket Kale. Formulation and Characterization of Eudragit RS 100 Nanosuspension for Ocular Delivery of Indomethacin. Research J. Pharm. and Tech.3 (3): July-Sept. 2010; Page 854-860.
33.    Dhiman SD and Thakur GS. “Nanosuspension: A recent approach for nano drug delivery system”, Int J Curr Pharm Res. 2010; 3(4): 96-101.
34.    Date AA, Kulkarni RM and Patravale VB et al. “Nanosuspensions: A promising drug delivery”, Journal of Pharmacy &Pharmacology. 2004; 56: 827–840.
35.    Müller RH, Grau MJ, Hildebrand GEet al. Increase of solubility of poorly soluble drugs by transfer to Dissocubes using high pressure homogenization. Proc Int Symp Control Rel Bioact Mater. 1999; 26: 112-113.
36.    Jagdale DM, Kamble VA and Kadam VJ et al, “Nanosuspension a novel drugdelivery system”, International Journal ofPharma and Bio Sciences. 2010; 1(4): 352-360.
37.    Kumar AN, Deecaraman M, Rani C et al, Nanosuspension technology and its applications in drug delivery. Asian J Pharma. 2009; 3(3): 168-173.DOI: 10.4103/0973-8398.56293
38.    Higgins JP. Spectroscopic approach for on-line monitoring of particle size during the processing of pharmaceutical nanoparticles. Anal Chem. 2003; 75(8): 1777-1785.doi: 10.1021/ac0207980.
39.    Young TJ, Mawson S, Johnston KP, Henriska IB, Pace GW, Mishra AK et al. Rapid expansion from supercritical to aqueous solution to produce submicron suspension of water insoluble drugs. Biotechnol Prog. 2000; 16(3): 402-407.doi: 10.1021/bp000032q.
40.    Setler P. Identifying new oral technologies to meet your drug delivery needs for the delivery of peptides and proteins and poorly soluble molecules. London: IIR Limited Drug delivery system; 1999.
41.    Muller RH, Jacobs C. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res 2002; 19: 189-94.doi: 10.1023/a:1014276917363.
42.    Yang JZ, Young AL, Chiang PC, Thurston A, Pretzer DK et al. Fluticasone and budesonide nanosuspensions for pulmonary delivery: Preparation, characterization, and pharmacokinetic studies. J Pharm Sci. 2008; 97(11): 4869-4878.doi: 10.1002/jps.21380
43.    Liang YC, Binner JG. Effect of triblock copolymer non-ionic surfactants on the rheology of 3 mol% yttria stabilised zirconia nanosuspensions. Ceram Int. 2008; 34: 293-7.
44.    Bond L, Allen S, Davies MC, Roberts CJ, Shivji AP, Tendler SJ, et al. Differential scanning calorimetry and scanning thermal microscopy analysis of pharmaceutical materials. Int J Pharm 2002; 243(1-2): 71-82.doi: 10.1016/s0378-5173(02)00239-9
45.    Yadav S. R & D Officer at lomus pharmaceutical PVT.LTd
46.    Squadrito F, Prosdocimi M, Altavilla D, Zingarelli B, Caputi A et al,  Cloricromene. Cardiovasc Drug Rev. 1991;4:357Y371.
47.    Pignatello R, Ricupero N, Bucolo C, Maugeri F, Maltese A, Puglisi G et al, Preparation and characterization of Eudragit retard nanosuspensions for the ocular delivery of cloricromene. AAPS Pharm sci tech. 2006;7(1):192-197.doi: 10.1208/pt070127
49.    Ahuja M, Dhake AS, Sharma SK, Majumdar DK et al, Diclofenac-loaded Eudragit S100 nanosuspension for ophthalmic delivery, Journal of Microencapsulation, 2011;28(1):37–45.
1.    doi: 10.3109/02652048.2010.523794
50.    Agnihotri SM, Vavia PR. Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application, Nanomedicine: Nanotechnology, Biology, and Medicine. 2009; 5: 90–95.DOI:10.1016/j.nano.2008.07.003
52.    Pignatello R, Bucolo C, Ferrara P, Maltese A, Pvleo A and Puglisi G et al Eudragit RS100 Nanosuspensions for the Ophthalmic Controlled Delivery of Ibuprofen. Eur. J. Pharm. Sci. 2002; 16:53-61.doi: 10.1016/s0928-0987(02)00057-x
53.    Kocbek P, Baumgartner S, Kristi J et al. Preparation and evaluation of nanosuspensions for enhancing dissolution of poorly soluble drugs, International Journal of Pharmaceutics. 2006; 312:179–186.doi: 10.1016/j.ijpharm.2006.01.008.
54.    Bucolo C, Maltese A, Puglisi G, Pignatello R et al, Enhanced ocularanti-inflammatory activity of ibuprofen carried by an eudragit RS100 nanoparticle suspension, Ophthalmic research. 2002;
55.    Tak D, Pahwa R, Kumar T, Ahuja M et al , Optimization of the interaction between diclofenac and ibuprofen with benzalkoniumchloride to prepare ocular nanosuspension, Recent patents on drug delivery and formulation. 2019;13(4) :301- 309.doi: 10.2174/1872211314666191218105826.
56.    https://www.healthlinkbc.
57.    Mandal B, Alexander SK, Riga TA et al.Sulfacetamide Loaded Eudragit RL100 Nanosuspension with Potentialfor Ocular Delivery, J Pharm Pharmaceut Sci.2010; 13(4): 510 - 523.PMID: 21486528
59.    Gupta H, Aqil M, Khar R K, Ali A, Bhatnagar A, Mittal G et al, Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug deliveryNanomedicine: Nanotechnology, Biology, and Medicine. 2010;6(2):324–333.doi: 10.1016/j.nano.2009.10.004.
60.    Ambhore N P, Dandagi P M and Gadad AP et al.Formulation and comparative evaluation of HPMC and water soluble chitosan-based sparfloxacin nanosuspension for ophthalmic delivery, Drug Delivery and Transl. Res. 2016; 6:48–56.doi: 10.1007/s13346-015-0262-y.
61.    Ohmori K, Hayashi K, Kaise T, Ohshima E,Kobayashi S,Yamazaki T, Mukouyama A et al. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug, Jpn. J. Pharmacol. 2002; 88: 379–397.doi: 10.1254/jjp.88.379.
62.    Leonardi A,  Quintieri L. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell, Expert Opin. Pharmacother. 2010; 11(6): 969–981.oi: 10.1517/14656561003694643.
63.    Brockman HL,Momsen MM,  Knudtson JR, Miller ST, Graff G, Yanni JM et al. Interactions of olopatadine and selected antihistamines with model and natural membranes, Ocul. Immunol. Inflamm. 2003; 11(4): 247–268.doi: 10.1076/ocii.
64.    Güvena U M, Evrim Yenilmezb. Olopatadine hydrochloride loaded Kollidon® SR nanoparticles for oculardelivery: Nanosuspension formulation and in vitro–in vivo evaluation,Journal of Drug Delivery Science and Technology. 2019; 51: 506–512.
66.    Soltani S, Milani PZ, Jalali BM, Jelvehgari M et al. Comparison of Different Nanosuspensions as Potential Ophthalmic Delivery Systems for Ketotifen Fumarate, Adv Pharm Bull. 2016; 6(3): 345-352.doi: 10.15171/apb.2016.046.
67.    Jansook P,MawPD, Soe HMHS,Chuangchunsong R, Saiborisuth K, Payonitikarn N,Autthateinchai R, Pruksakorn P et al. Development of amphotericin B nanosuspensions for fungal keratitistherapy: effect of self-assembled γ-cyclodextrin, Journal of Pharmaceutical Investigation, 2020.
68.    Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB and RM Khalil et al. Nanosuspension as an Ophthalmic Delivery System for Certain Glucocorticoid Drugs, International Journal of Pharmaceutics. 2007; 340: 126-133.
69.    Lucas S. “The Pharmacology of Indomethacin.” Headache.2016; 56(2):436-446. d0i:10.1111/head.12769.
70.    Bodmeier R and Chen H. Indomethacin polymeric nanosuspensions prepared by microfluidization, journal of controlled release. 1990; 12: 223-233.
71.    American society of health-system pharmacist,inc.disclaimer(>meds)
72.    Dandagi P, Kerur S, Mastiholimath V,Gadad A and Kulkarni A et al. Polymeric ocular nanosuspension for controlled release ofacyclovir: in vitro release and ocular distribution, Iranian Journal of Pharmaceutical Research. 2009; 8(2): 79-86. 10.22037/IJPR.2010.793.
73.    Pignatello R, Bucolo C, Spedalieri G, Maltese A, Puglisi G et al. Flurbiprofen-loadedacrylate polymer nanosuspension for ophthalmic application, Biomaterials. 2002;23: 3247-3255.
74.    Joshi H P. Nanosuspension based electrolyte sensitive in situ gel for topical ocular delivery of natamycin(2019). Electronic Theses and Dissertations. 1624.
75.    Nakarani M, Patel P, Patel J,  Patel P, Murthy RSR, Vaghani SS et al. Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with a Marketed Formulation, Sci Pharm. 2010; 78: 345–361.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

56th percentile
Powered by  Scopus

SCImago Journal & Country Rank

Recent Articles


Not Available